Last Update 16 Jul 26
Fair value Decreased 33%CERT: Growth Reset And Lower P E Multiple Will Pressure Returns
Analysts have reduced their fair value estimate for Certara from $9.00 to $6.00, citing a reset in revenue growth expectations, continued solid profitability, and a lower assumed future P/E multiple.
Analyst Commentary
Recent Street research on Certara highlights a split view, with some analysts pointing to supportive sector valuation data and others cutting price targets in response to tempered growth expectations and a lower assumed future P/E multiple.
One research house pointed to the acquisition of peer Simulations Plus at a premium valuation as a reference point, arguing that Certara remains highly profitable with several potential long-term growth drivers. This view uses private market activity as a comparison for how software driven drug development assets are being valued outside public markets, while acknowledging that Certara is currently trading below those implied levels.
At the same time, several bearish analysts have taken a more cautious stance, revisiting their Certara models and trimming price targets to reflect more conservative revenue assumptions, execution risk under new leadership, and uncertainty around how quickly growth could stabilize.
Bearish Takeaways
- Bearish analysts have reduced price targets for Certara, which points to concern that previous expectations for revenue growth and valuation multiples may have been too optimistic given current information.
- These lower targets often reflect caution around execution as the company moves through its investment period under new leadership, with questions about how efficiently spending will convert into steadier growth.
- The reset in assumed future P/E multiples suggests some analysts see a risk that Certara’s profitability profile and growth outlook may not fully support earlier valuation levels.
- Overall, the clustering of price target cuts signals a more guarded stance on Certara’s near to medium term growth visibility and the potential for further volatility if revenue trends or margins differ from expectations.
What’s in the News for Certara
- Certara announced a collaboration with Nvidia to integrate the Nvidia BioNeMo Agent Toolkit into its AI driven drug discovery and development platform, combining Certara’s biosimulation software, regulatory expertise, and proprietary datasets with Nvidia’s agentic AI technology to support a wide range of pharmaceutical R&D activities. (Source: company announcement, Nvidia partnership coverage)
- BlackRock filed an amended Schedule 13G/A reporting beneficial ownership of 18,032,062 Certara shares, representing 11.6% of the common stock class, with sole voting power over 17,841,248 shares. (Source: SEC Schedule 13G/A filing)
- Certara launched Bio Venture Catalyst, an integrated advisory offering aimed at emerging biotech companies from pre seed through Series B+ development, combining scientific, regulatory, commercial, and investor focused support to help clients assess opportunities and plan development and commercialization paths. (Source: company product announcement)
- Certara’s index membership shifted as it was added to the Russell 2000, Russell 2000 Value, and Russell 2000 Dynamic indexes, and removed from several Russell 1000 and Midcap benchmarks, aligning the stock more closely with small cap and value oriented indices. (Source: index reconstitution updates)
- Certara reported a share repurchase of 5,814,484 shares for US$39.89m in the first quarter of 2026, completing a total buyback of 9,182,858 shares for US$80.9m under the program announced on April 14, 2025, and updated full year 2026 revenue guidance to a range of US$395m to US$405m with fully diluted shares expected between 157m and 159m. (Source: company buyback and guidance update)
Valuation Changes for Certara
- Fair Value, reduced from $9.00 to $6.00, reflects a cut of roughly one third in the updated assessment for Certara.
- Discount Rate, adjusted slightly from 8.82% to 8.70%, indicates only a small change in the required return used in the model.
- Revenue Growth, revised from 7.41% to 0.08%, represents a very large step down in assumed forward growth for Certara.
- Net Profit Margin, moved from 4.12% to 6.69%, points to higher modeled profitability even as revenue growth assumptions have been reset.
- Future P/E, reduced from 84.33x to 38.63x, shows a substantial cut in the valuation multiple applied to Certara’s earnings in the updated framework.
Catalysts
About Certara
Certara provides biosimulation software and technology enabled services that support model informed drug development across the pharmaceutical and biotech industry.
What are the underlying business or industry changes driving this perspective?
- Although adoption of model informed drug development is broadening across dosing, efficacy and toxicity work, the recent slowness in Tier 1 services bookings and weaker regulatory services demand could limit how much of this interest converts into higher services revenue and profit growth over the next few years.
- While demand for QSP and biosimulation related to reduced animal testing and FDA guidance on new approach methodologies is building, the current mix of QSP toward services and the low single digit outlook for services growth may constrain margin expansion and earnings growth if software based QSP uptake is slower than hoped.
- Although Simcyp software and Chemaxon are contributing to software revenue and bookings, the shift toward more license based and Chemaxon driven sales reduces the proportion of ratable revenue. This could add volatility to reported revenue and earnings despite healthy trailing 12 month software bookings.
- While new cloud and AI embedded launches such as Phoenix Cloud, Pinnacle 21 Enterprise and CertaraIQ are aimed at expanding usage across discovery, preclinical and clinical phases, pharma customers are still working through internal AI deployment, budgets and data governance. This may delay the timing of broader software adoption and its impact on recurring revenue and EBITDA margins.
- Despite a growing Tier 2 and Tier 3 customer base and increased wallet share over time, ongoing hesitancy and slower decision making among large pharma, combined with the pending outcome of the regulatory services review, introduces uncertainty for services bookings and cash generation that support net income and share repurchases.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Certara compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Certara's revenue will remain fairly flat over the next 3 years.
- The bearish analysts are not forecasting that Certara will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Certara's profit margin will increase from -3.6% to the average US Healthcare Services industry of 6.7% in 3 years.
- If Certara's profit margin were to converge on the industry average, you could expect earnings to reach $28.1 million (and earnings per share of $0.2) by about July 2029, up from -$15.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $36.6 million in earnings, and the most bearish expecting $-13.0 million.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 38.7x on those 2029 earnings, up from -72.7x today. This future PE is greater than the current PE for the US Healthcare Services industry at 34.0x.
- The bearish analysts expect the number of shares outstanding to decline by 3.15% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.7%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Broadening use of model informed drug development across dosing, efficacy and toxicity, combined with growing adoption among both large pharma and smaller biotech customers, could support higher long term software and services demand than expected, which would feed into stronger revenue and earnings.
- Certara’s focus on QSP and biosimulation, supported by FDA guidance that promotes new approach methodologies and reduced animal testing, may create a structural tailwind for its QSP software and services over many years, which could lift net margins and overall profitability.
- The ramp of new products such as Pinnacle 21 Enterprise, Phoenix Cloud and CertaraIQ, alongside successful integration of Chemaxon with a path to corporate average margins, may increase the software mix and ratable revenue base over time, which could improve EBITDA margins and earnings growth.
- If Tier 1 customer hesitancy in services proves temporary and stabilizes as pharma budgets and pricing visibility improve, while Tier 2 and Tier 3 continue to show good momentum, services bookings and revenue could reaccelerate, supporting higher cash generation and net income.
- Ongoing R&D investment at 10% of revenue, with AI embedded across products and the ability to reuse foundational QSP models, could improve operating leverage over the long run, which may support higher adjusted EPS and expand net margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Certara is $6.0, which represents up to two standard deviations below the consensus price target of $7.53. This valuation is based on what can be assumed as the expectations of Certara's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $6.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $420.8 million, earnings will come to $28.1 million, and it would be trading on a PE ratio of 38.7x, assuming you use a discount rate of 8.7%.
- Given the current share price of $7.06, the analyst price target of $6.0 is 17.7% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Certara?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
